（记者 曾健辉） 截至发稿，达安基因市值为97亿元。 每经头条（nbdtoutiao）——段睿：我与蔡磊是 "找钥匙的人"，纵使生前寻不到，也要为其他渐冻症患 者铺就近路 每经AI快讯，达安基因（SZ 002030，收盘价：6.9元）11月17日晚间发布公告称，2025年11月15日，广 州金融控股集团有限公司、广州生物医药与健康产业投资有限公司与广州医药集团有限公司签署了《关 于广州达安基因股份有限公司控股权收购框架协议》，广药集团拟根据《框架协议》项下的条款和条件 受让或指定其全资子公司等关联方受让广州金控集团持有的广州广永科技发展有限公司100%股权而间 接控制广永科技持有的广州达安基因股份有限公司约2.33亿股股份；并另行通过协议转让方式受让广州 金控集团持有的达安基因约7017万股股份和广州健康产投持有的达安基因约7017万股股份。本次权益变 动如实施完成，广药集团将成为公司间接控股股东，合计控制公司约3.74亿股股份，占公司总股本的 26.63%；广州金控集团仍通过广州健康产投持有公司约7017万股股份，持股比例为5%。公司的控股股 东仍为广永科技，实际控制人仍为广州市人民政府，不会发生变化。 2 ...

每经AI快讯，利德曼（SZ 300289，收盘价：9元）11月13日晚间发布公告称，公司第六届第七次董事会 会议于2025年11月13日在北京市北京经济技术开发区兴海路5号公司二层会议室以现场方式召开。会议 审议了《关于上市公司进行重大资产重组的议案》等文件。 2025年1至6月份，利德曼的营业收入构成为：生物制品业占比86.79%，房屋租赁占比12.96%，其他业 务占比0.25%。 （记者 王晓波） 截至发稿，利德曼市值为49亿元。 每经头条（nbdtoutiao）——"银行直供房，不计成本卖！"有的半价出售，众多刚需还不知道！银行用 过的房很抢手，有人加价100万元抢拍 ...

Group 1 - The core point of the article is that Kehua Bio (SZ 002022) held its 17th meeting of the 10th board of directors on October 13, 2025, via telecommunication to discuss the proposal for the reappointment of the accounting firm [1] - For the first half of 2025, Kehua Bio's revenue composition is entirely from the bioproducts sector, accounting for 100.0% [1] - As of the time of reporting, Kehua Bio has a market capitalization of 3.3 billion yuan [1]

Group 1 - Lidman announced an investor survey scheduled for September 8-9 and 11-12, 2025, with the participation of Vice President and Board Secretary Zhang Lihua [1] - For the first half of 2025, Lidman's revenue composition was as follows: 86.79% from the biopharmaceutical sector, 12.96% from property leasing, and 0.25% from other businesses [1] - As of the report, Lidman's market capitalization was 4.3 billion yuan [2]

Company Overview - DaAn Gene (SZ 002030) announced its first board meeting of the ninth session held on August 28, 2025, in Guangzhou, discussing the revision and formulation of certain company systems [1] Financial Performance - For the first half of 2025, DaAn Gene's revenue composition was as follows: 95.68% from the bioproducts sector and 4.32% from financial services [1]

Group 1 - The core point of the article is that Kehua Bio (SZ 002022) announced the receipt of a medical device registration certificate for its "Human Papillomavirus Nucleic Acid Typing Detection Kit" from the National Medical Products Administration [1] - As of January to June 2025, the revenue composition of Kehua Bio is 100% from the biopharmaceutical sector [1] - Kehua Bio's market capitalization is currently 3.8 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

Group 1 - Lidman (SZ 300289, closing price: 8.89 yuan) announced on August 26 that its sixth fifth board meeting was held via communication method, discussing the proposal for the full text and summary of the 2025 semi-annual report [1] - For the year 2024, Lidman's revenue composition is as follows: 90.84% from the biopharmaceutical industry, 8.98% from property leasing, and 0.17% from services [1] - As of the report date, Lidman's market capitalization is 4.8 billion yuan [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices of related listed companies [1]

Group 1 - The core point of the article is that Da An Gene has received a medical device registration certificate from the National Medical Products Administration for its "Human MTHFR Gene Typing Detection Kit" [2] - In the fiscal year 2024, Da An Gene's revenue composition is projected to be 96.2% from the biopharmaceutical sector and 3.8% from financial services [2]

Group 1 - The core point of the article is that Kehua Bio has received a medical device registration certificate from the National Medical Products Administration for its product "Treponema pallidum antibody quality control product" [2] - Kehua Bio's revenue composition for the year 2024 is expected to be 100.0% from the biopharmaceutical industry [2]

Core Insights - The company Kehua Bio-engineering has received a medical device registration certificate from the Shanghai Municipal Drug Administration for its product "C-Reactive Protein (CRP) Test Kit" [2] - For the year 2024, the company's revenue composition is expected to be 100.0% from the biopharmaceutical sector [2]